Moderna aims to roll out a combined COVID-flu-RSV booster vaccine in late 2023, the US pharmaceutical firm says, hoping a joint shot will encourage people to get an annual vaccination.
The single vaccine for COVID-19, influenza and respiratory syncytial virus — a common virus that causes the cold, but can be more serious for infants and elderly people — could appear on the market before 2024.
“Best-case scenario will be the fall of ’23,” Moderna chief executive Stephane Bancel tells a virtual World Economic Forum roundtable session.
“I don’t think it would happen in every country, but we believe it’s possible to happen in some countries next year. Our goal is to be able to have a single annual booster so that we don’t have compliance issues where people don’t want to get two to three shots a winter, but to get one dose.”
Is our work important to you?
Do you rely on The Times of Israel for accurate and insightful news on Israel and the Jewish world? If so, please join The Times of Israel Community. For as little as $6/month, you will:
Join the Times of Israel Community
Join our Community
Already a member? Sign in to stop seeing this
You're a dedicated reader
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we started the Times of Israel eleven years ago - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Thank you,
David Horovitz, Founding Editor of The Times of Israel
Join Our Community
Join Our Community
Already a member? Sign in to stop seeing this